

VOLUME CONTENTS AND INDEX

No. 1, MARCH 1992

**Bioregulation of Kinins: Kallikreins, Kininogens, and Kininases.** K. D. Bhoola, C. D. Figueroa, and Karen Worthy

I. Overview and perspectives	4
II. Historical reminiscences	5
III. Genealogy, chemical structure, properties, and functional importance	6
A. Kallikreins	6
1. Plasma kallikrein	6
2. Tissue (glandular, cell) kallikrein	9
3. T-kininogenase	18
B. Kininogens	18
1. Kininogens	18
2. T-kininogens	22
3. Avian (ornitho) kininogens	23
C. Kininases	23
1. Kininase I carboxypeptidases	23
2. Kininase II-peptidases	24
3. Additional kinin peptidases	26
D. Kinins	26
1. Kallidin and bradykinin	26
IV. Cellular biology and functional importance in cells	36
A. Renal cells	36
1. Kallikrein: tissue kallikrein	36
2. Kininogen	38
3. Kininases	39
4. Kinins	39
5. Functional importance	41
B. Sweat gland cells	44
1. Kininogenases and kininogen	44
2. Kinins	45
C. Brain tissue and neuronal cells	45
1. Kininogenases and tissue kallikrein	46
2. Kininogen	46
3. Kininases	46
4. Kinins	47
D. Prolactin-secreting cells	49
1. Kininogenases	49
E. Cardiac myocytes	51
1. Kininogenases	51
2. Kinins	51
2. Functional importance in myocardial ischaemia and infarction	52
F. Spermatozoa, Sertoli cells, and epithelial cells of the prostate, epididymis, and coagulating glands	52
1. Kininogenases	52
2. Kininases	53
3. Kininogens and kinins	53
G. Leucocytes	53
1. Kininogenases	53
2. Identification of tissue kallikrein and kininogen in human neutrophils	54
3. Neutrophil function in inflammation	56
V. Selected topics concerning the clinical pharmacology of the kallikrein-kinin system	58
A. Allergic rhinitis	58
B. Asthma	58
C. Arthritis	59
1. Kallikreins	59
2. Kininogens	60
3. Kininases	60
4. Kinins	60
VI. References	61

**Actions of Adrenergic and Cholinergic Drugs on Renal Tubular Cells. Lal C. Garg**

I. Introduction	81
II. General considerations	82
A. General mechanisms of drug action	82
B. Special characteristics of the kidney	83
III. Pharmacology of adrenergic drugs	85
A. Actions of the whole kidney	85
B. Adrenergic receptors	86
C. Actions on renal tubular cells	87
1. Proximal tubule	87
2. Loop of Henle	89
3. Distal convoluted tubule	90
4. Collecting duct	90
5. Cultured cells	92
IV. Pharmacology of cholinergic drugs	92
A. Actions on the whole kidney	92
B. Cholinergic receptors	93
C. Signal transduction	94
D. Actions on renal tubular cells	95
V. Pharmacological implications of medullary interstitial hypertonicity	96
A. Effects on renal tubular cells	96
B. Effects on signal transduction	96
C. Effects of ligand binding to receptors	97
D. Implications	98
VI. Summary and conclusions	98
VII. References	99

**Functional Consequences of Streptozotocin-induced Diabetes Mellitus, with Particular Reference to the Cardiovascular System. Kerry C. Tomlinson, Sheila M. Gardiner, R. Anthony Hebden, and Terence Bennett**

I. Introduction	104
II. Endocrine systems	105
A. Vasopressin	105
B. Renin-angiotensin system	107
C. Aldosterone	109
D. Glucocorticoids	109
E. Atrial natriuretic peptide	110
F. Thyroid function	111
G. Glucagon	112
III. Kidney	112
A. Glomerular hyperfiltration	113
B. Fluid and electrolyte handling	115
C. Summary	115
IV. Liver	116
V. Autonomic nervous system	117
A. Structural changes	117
B. Biochemical and functional changes	118
1. Noradrenergic and cholinergic neurotransmission	118
2. Peptidergic mechanisms	119
C. Summary	120
VI. Central nervous system	121
A. Insulin and the central nervous system	121
B. Structural changes	122
C. Neurotransmitter systems	122
1. Noradrenaline	123
2. Dopamine	123
3. 5-Hydroxytryptamine	123
4. Adrenaline	124
5. Acetylcholine	124
6. Hypothalamic neuropeptides	124
D. Central nervous control of the cardiovascular system	124
E. Summary	126
VII. Myocardium	126
A. Chronotropic function	126
B. Inotropic function	127
C. Cardiac autonomic receptors	128
1. $\beta$ -Adrenoceptors	128

2. $\alpha$ -Adrenoceptors .....	129
3. Cholinoceptors .....	130
D. Summary .....	130
VIII. Vasculature .....	131
A. In vitro studies of vascular smooth muscle function .....	131
1. Vasoconstrictor mechanisms .....	131
2. Vasodilator mechanisms .....	134
B. In vivo studies of vascular smooth muscle function .....	134
C. In vitro and in vivo studies of endothelial function .....	135
D. Summary .....	136
IX. Integrated cardiovascular function .....	138
A. Heart rate .....	138
B. Blood pressure .....	138
C. Baroreflexes .....	140
D. Summary .....	141
X. References .....	141

## NO. 2, JUNE 1992

**Benzodiazepines: Use, Abuse, and Consequences.** James H. Woods, Jonathan L. Katz, and Gail Winger

I. Introduction .....	155
A. Recent reviews .....	155
B. Approach of the present review .....	156
C. Definition of abuse liability and organization of the review .....	156
D. New concerns .....	156
II. Studies of drug taking and drug seeking .....	158
A. Introduction .....	158
B. Studies in animals .....	158
1. Studies of oral drug ingestion .....	158
2. Studies of place preference .....	159
3. Drug infusion studies .....	160
4. Summary and conclusions .....	162
C. Studies in humans .....	163
1. Studies in normal subjects .....	163
2. Studies in anxious subjects .....	164
3. Subjects undergoing benzodiazepine withdrawal .....	165
4. Studies in subjects with histories of sedative abuse .....	165
5. Studies in alcoholics .....	167
6. Summary and discussion .....	168
D. Summary and discussion .....	168
III. Studies of physiological dependence .....	169
A. Introduction .....	169
B. Studies in animals .....	170
1. Cross-dependence studies .....	170
2. Primary dependence studies .....	172
3. Procedures hypothesized to measure withdrawal anxiety .....	183
4. Summary and discussion .....	184
C. Studies in humans .....	186
1. Dependence on short half-life benzodiazepines .....	186
2. Comparisons of short and longer half-life benzodiazepines .....	187
3. Studies of parameters that might affect withdrawal .....	195
4. Comparisons of dependence on benzodiazepine and nonbenzodiazepine anxiolytics .....	198
5. Surveys of dependence .....	199
6. Benzodiazepine dependence in the elderly .....	200
7. Studies of rebound insomnia .....	200
8. Outcome and long-term withdrawal .....	203
9. Summary and discussion .....	204
D. Summary and discussion .....	205
IV. Adverse behavioral consequences of benzodiazepine use .....	207
A. Introduction .....	207
B. Effects of benzodiazepines on psychomotor performance .....	207
1. Effects in normal subjects .....	207
2. Effects in anxious and insomniac subjects .....	211

3. Effects in elderly subjects	213
4. Effects in subjects with histories of sedative abuse	214
5. Summary and discussion	214
C. Effects of benzodiazepines on recall	214
1. Effects of acute dosing in normal volunteers	215
2. Amnestic versus sedative effects of benzodiazepines	220
3. Effects of chronic dosing on normal volunteers	224
4. Effects of chronic dosing on patients	225
5. Effects of benzodiazepines on episodic and knowledge memory	226
6. Transient global amnesia	228
7. Summary	229
D. Effects of benzodiazepines on the risk of accidents	229
1. Effects on the risk of automobile accidents	229
2. Effects on the risk of other types of accidents	233
3. Summary and discussion	237
V. Epidemiology of benzodiazepine use and misuse	238
A. Introduction	238
1. Importance of the context of utilization	238
2. Previous findings and current evidence	238
B. Prescription Sales	239
1. Studies of wholesale data	240
2. Studies of retail data	241
3. Summary and discussion	249
C. Surveys of prescribing patterns	250
1. Surveys of physicians	251
2. Surveys of prescriptions	254
3. Summary and discussion	260
D. Interview surveys of consumption	261
1. National surveys	262
2. Regional and other surveys	264
3. Interview data concerning patterns of use	270
4. Interview data concerning long-term use	272
5. Studies including ratings of psychological health	276
6. Summary and discussion	280
E. Surveys of use in special populations	282
1. Elderly patients	282
2. Children and adolescents	283
3. Mentally retarded patients	283
F. Surveys of misuse and recreational use	286
1. Prevalence and patterns of misuse	287
2. Surveys of drug overdose or drug-associated deaths	302
3. Mortality and morbidity associated with benzodiazepine misuse or dependence	312
4. Summary and conclusions	313
G. Studies of effects of benzodiazepine restrictions	314
1. The New York State regulation	314
2. Study of immediate clinical effects	314
3. Studies of effects on prescribing	315
4. Study of effects on overdoses	315
5. Summary and discussion	316
VI. General summary and discussion	316
A. Epidemiological findings	317
1. Frequencies of use	317
2. Use among the elderly	317
3. General conclusions	318
B. Physiological dependence	318
1. Pharmacokinetic factors	318
2. Clinical significance	318
3. Research needs	319
C. Reinforcing effects	320
D. Effects on performance	321
E. New leads in development of anxiolytics and hypnotics	322
F. Conclusion	322
VII. References	323

No. 3, SEPTEMBER 1992

**International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification**

I. Preface. Paul M. Vanhoutte

349

**II. Definition of Pharmacological Receptors.** Terry P. Kenakin, Richard A. Bond, and Tom I. Bonner

I. Introduction	351
II. Receptors: an operational definition	351
III. Functional tissue systems	352
IV. Pharmacological criteria for classification	352
A. Recognition	352
1. Antagonists	353
2. Agonists	355
B. Transduction	355
V. Molecular biology relevant to receptor characterization	356
VI. Basis for a molecular nomenclature	357
VII. Parallel pharmacological and molecular nomenclatures	359
VIII. Suggested rules for naming receptors	360
IX. Conclusions	360
X. References	361

**III. Classification of Calcium Channels and the Sites of Action of Drugs Modifying Channel Function.** M. Spedding and R. Paoletti

I. Introduction	363
II. Historical aspects	365
III. Criteria for classification	365
A. Channel classification	365
1. Functional studies	365
2. Radioligand-binding and autoradiographic studies	366
3. Molecular biology	367
B. Classification of binding sites for drugs on calcium channels	367
IV. Types of voltage-dependent calcium channels	367
A. Voltage-dependent Ca <sup>2+</sup> -selective channels	367
1. L-type channels	367
2. T-type channels	369
3. N-type channels	369
4. P-type channels	370
B. Other Ca <sup>2+</sup> -selective channels	370
C. Other voltage-dependent ion channels	371
D. Nonchannel targets	371
V. Drug-binding sites on calcium channel proteins	371
A. Class 1: L channel-selective agents	371
a. Dihydropyridines	371
b. Benzothiazepines	372
c. Verapamil-like agents	372
B. Class 2: agents interacting with other voltage-dependent Ca <sup>2+</sup> channels	373
C. Class 3: nonselective channel modulators	373
VI. Nomenclature	373
VII. References	373

**Physiology and Pharmacology of Endogenous Digitalis-like Factors.** A. Goto, K. Yamada, N. Yagi, M. Yoshioka, and T. Sugimoto

I. Introduction	377
II. Search for an endogenous digitalis-like factor	378
A. Definition of the endogenous digitalis-like factor	378
B. Distinction between endogenous digitalis-like factor and Na <sup>+</sup> ,K <sup>+</sup> -ATPase inhibitors	379
C. Detection of endogenous digitalis-like factor	380
III. Candidates for endogenous digitalis-like factor	382
A. Lipids	382
B. Steroids	384
1. Modification of natural or synthetic steroids	384
2. Bufodienolides	384
3. Cardenolides	385
4. Glycosteroids	386
5. Adrenal or gonadal steroids	386
6. Canrenone	386
C. Peptides	386
D. Unknown substances	387

E. Other known substances .....	388
1. Ascorbic acid .....	388
2. Lignans .....	388
3. Urodienone .....	388
4. Hemin .....	388
IV. Ouabain-like compound .....	389
A. Identification of ouabain-like compound .....	389
B. Origin of ouabain-like compound .....	389
C. Putative physiological roles of ouabain-like compound .....	391
1. Physiological implications of ouabain-like compound .....	391
2. Tissue selectivity of the action of ouabain-like compound .....	392
3. Positive inotropic effect .....	392
4. Natriuretic effect .....	392
5. Hypertensive effect .....	393
V. Conclusions .....	394
VI. References .....	395

### 5-Hydroxytryptamine Receptors. Emilie Zifa and Gilles Fillion

I. Introduction .....	402
II. Classification of serotonin receptors .....	403
III. 5-HT <sub>1</sub> receptors .....	405
A. 5-HT <sub>1A</sub> receptor subtype .....	405
1. Selective radioligands and pharmacological properties .....	405
2. Regional distribution within the brain .....	408
3. Cellular localization .....	408
4. Molecular structure .....	408
5. Transduction systems .....	409
6. Possible heterogeneity of the 5-HT <sub>1A</sub> receptor subtype .....	411
7. Regulation .....	411
8. Cellular functions .....	414
9. 5-HT <sub>1A</sub> receptors and behavior .....	414
B. 5-HT <sub>1B</sub> receptor subtype .....	417
1. Selective radioligands and pharmacological properties .....	417
2. Regional distribution .....	417
3. Cellular localization .....	417
4. Molecular structure .....	417
5. Transduction system .....	419
6. Regulation .....	419
7. Cellular functions .....	419
8. 5-HT <sub>1B</sub> receptors and behavior .....	420
C. 5-HT <sub>1D</sub> receptor subtype .....	420
1. Selective radioligands and pharmacological properties .....	420
2. Regional distribution .....	422
3. Cellular localization .....	422
4. Molecular structure .....	423
5. Transduction system .....	423
6. Regulation .....	424
7. Cellular functions .....	424
8. 5-HT <sub>1D</sub> receptors and behavior .....	424
9. Conclusion .....	424
IV. 5-HT <sub>2</sub> receptors .....	424
A. "Classical" 5-HT <sub>2</sub> receptor .....	424
1. Selective radioligands and pharmacological properties .....	424
2. Regional distribution in the brain .....	425
3. Cellular localization .....	425
4. Molecular structure .....	426
5. Transduction systems .....	427
6. Regulation .....	427
7. Cellular functions .....	429
8. 5-HT <sub>2</sub> receptors and behavior .....	429
B. 5-HT <sub>1C</sub> receptors .....	430
1. Selective radioligands and pharmacological properties .....	430
2. Regional distribution within the brain .....	431
3. Cellular localization .....	431
4. Molecular structure .....	431
5. Transduction system .....	431
6. Regulation .....	432

7. Cellular functions	432
8. 5-HT <sub>1C</sub> receptors and behavior	432
V. 5-HT <sub>2</sub> receptors	432
A. Selective radioligands and pharmacological properties	433
B. Regional distribution within the brain	433
C. Molecular structure	435
D. Transduction system	435
E. Regulation	437
F. Cellular functions	437
G. 5-HT <sub>2</sub> receptors and behavior	437
VI. Other 5-HT receptors	439
VII. Conclusion	440
VIII. References	440

## No. 4, DECEMBER 1992

**Pentostatin: Future Directions.** Wayne D. Klohs and Alan J. Kraker

I. Introduction	459
II. Pentostatin effects on the biochemistry of adenosine deaminase	460
A. Inhibition of adenosine deaminase	460
B. Pentostatin inhibition of adenosine deaminase isoenzymes	460
C. Physical biochemistry	461
D. Stereochemistry of inhibitors	461
III. Cell biology of pentostatin	461
A. Adenosine and deoxyadenosine metabolism	461
B. Tissue specificity of adenosine deaminase and enzymes in purine metabolism	461
C. Cell cycle effect	462
IV. Molecular pharmacology	463
A. In vitro cytotoxicity	463
B. Deoxycytidine reversal of pentostatin-deoxyadenosine-induced cytotoxicity	464
C. Involvement of dATP in pentostatin-induced cytotoxicity	465
D. Inhibition of interleukin 2	465
E. Inhibition of RNA synthesis	465
1. Pentostatin-induced inhibition of methylation reactions	466
F. Pentostatin effects on DNA strand breakage	466
G. Resistance to pentostatin	467
V. Activity against mouse tumors and human tumor xenografts	468
A. Antitumor screening results for pentostatin alone	468
B. Effect of pentostatin on the antitumor activities of adenosine analogs in vivo	468
VI. Other biological activities	469
A. Immunosuppressive actions of pentostatin	469
B. Antiviral activity of pentostatin alone and in combination with 9- $\beta$ -D-arabinofuranosyladenine	471
C. Effect of pentostatin on adenosine's involvement in central nervous system functions	472
D. Effect of pentostatin on malaria parasites	473
VII. Conclusions	473
VIII. References	473

**Atrial Natriuretic Peptide: Synthesis, Release, and Metabolism.** Heikki Ruskoaho

I. Introduction	481
II. Structure, synthesis, and processing of atrial natriuretic peptide	482
A. Structure of atrial natriuretic peptide	482
B. Cardiac biosynthesis	483
1. Developmental regulation	483
2. Atrial and ventricular expression of atrial natriuretic peptide in the normal adult heart	484
3. Structure of the atrial natriuretic peptide gene	485
4. Regulatory sequences of the atrial natriuretic peptide gene	486
C. Processing of atrial natriuretic peptide	487
1. Atrial natriuretic peptide posttranslational processing and processing products	487
2. Site of atrial natriuretic peptide processing and processing enzymes	489
D. Extracardiac expression of atrial natriuretic peptide	491
E. Other atrial natriuretic peptide-like peptides	493
1. Urodilatin	493
2. Brain natriuretic peptide and related peptides	494
3. C-type natriuretic peptide	495

III. Factors affecting atrial natriuretic peptide gene expression .....	496
A. Atrial atrial natriuretic peptide gene expression in pressure and volume overload .....	496
1. Animal experiments .....	496
2. Human studies .....	496
B. Ventricular atrial natriuretic peptide gene expression in pressure and volume overload and cardiac hypertrophy .....	504
1. Animal experiments .....	504
2. Cardiac overload in humans .....	507
3. Summary of the effect of pressure and volume overload on atrial natriuretic peptide gene expression .....	508
4. Expression of brain natriuretic peptide in ventricular hypertrophy .....	509
C. Glucocorticoids .....	509
D. Thyroid hormones .....	510
E. Other humoral and growth factors .....	510
1. Endothelin .....	510
2. Catecholamines .....	511
3. Growth factors .....	511
4. Prostaglandins and other products of arachidonic acid metabolism .....	511
5. Other substances .....	512
F. Mechanisms of induction of atrial natriuretic peptide-coding gene in cardiac myocytes .....	512
1. Stimuli for atrial natriuretic peptide gene expression .....	512
2. Molecular basis for activation of atrial natriuretic peptide gene expression .....	513
IV. Regulation of atrial natriuretic peptide secretion .....	516
A. Methods used in the study of atrial natriuretic peptide secretion .....	516
1. In vivo experiments .....	517
2. Isolated perfused heart and isolated atria preparations .....	517
3. Cell cultures .....	517
B. Effect of stretching of myocytes .....	518
1. In vitro models .....	518
2. In vivo studies .....	519
C. Rate of contraction .....	524
1. Effect of heart rate on atrial natriuretic peptide release in vivo and in vitro .....	524
2. Mechanisms of tachycardia-induced atrial natriuretic peptide release .....	524
D. Effect of neurohumoral agonists .....	526
1. Epinephrine, norepinephrine, and other drugs acting on $\alpha$ -adrenoceptors .....	526
2. Isoproterenol and other drugs acting on $\beta$ -adrenoceptors .....	527
3. Acetylcholine and cholinergic agonists .....	528
4. Vasopressin .....	529
5. Angiotensin .....	531
E. Endothelium-derived contracting and relaxing factors .....	532
1. Endothelins .....	532
2. Endothelium-derived relaxing factor .....	533
3. Arachidonic acid and its metabolites .....	534
F. Role of the peripheral and central nervous system .....	534
1. Pithed rats .....	535
2. Cardiac denervation and stimulation of sympathetic and parasympathetic nerves .....	535
3. Pituitary, hypothalamus, and other areas in the central nervous system .....	536
G. Other secretagogues .....	537
1. Hypoxia and hypercapnia .....	537
2. Myocardial ischemia and metabolic changes .....	538
3. Osmolality .....	539
4. Opiates .....	540
5. Other peptides .....	541
6. Other stimuli affecting atrial natriuretic peptide release .....	541
H. Regulation of ventricular release of atrial natriuretic peptide .....	542
I. Cellular signals regulating atrial natriuretic peptide secretion .....	544
1. Role of phosphoinositide hydrolysis and protein kinase C .....	544
2. Cytosolic $Ca^{2+}$ homeostasis and atrial natriuretic peptide secretion .....	545
3. Role of cyclic AMP and GMP in atrial natriuretic peptide release .....	547



4. Mechanisms of endothelin-induced atrial natriuretic peptide release . . . . . 548

5. Mechanisms of stretch-induced atrial natriuretic peptide release . . . . . 550

6. Cellular signals regulating ventricular atrial natriuretic peptide secretion . . . . . 552

7. Summary . . . . . 553

V. Metabolism of circulating atrial natriuretic peptide . . . . . 553

    A. Pharmacokinetics of atrial natriuretic peptide . . . . . 554

    B. Elimination of atrial natriuretic peptide by different tissues . . . . . 554

    C. Pathways of atrial natriuretic peptide elimination . . . . . 555

        1. Receptor-mediated clearance of atrial natriuretic peptide . . . . . 555

        2. Neutral endopeptidase . . . . . 558

        3. Other inactivation pathways . . . . . 559

    D. Inhibitors of atrial natriuretic peptide elimination . . . . . 560

        1. ANP<sub>C</sub> receptor ligands . . . . . 560

        2. Neutral endopeptidase inhibitors . . . . . 562

        3. Effect of combined inhibition of ANP<sub>C</sub> receptors and neutral endopeptidase . . . . . 569

VI. Pharmacological implications . . . . . 571

    A. Rationale for the pharmacological use of atrial natriuretic peptide . . . . . 571

    B. Therapeutic possibilities to affect atrial natriuretic peptide hormonal system . . . . . 574

        1. ANP<sub>A</sub> receptor analogs . . . . . 575

        2. Inhibitors of atrial natriuretic peptide metabolism . . . . . 575

        3. Atrial natriuretic peptide antagonists or inhibitors . . . . . 576

VII. References . . . . . 576

**Statement of Ownership, Management and Circulation**  
(Required by 39 U.S.C. 3686)

1A. Title of Publication <b>PHARMACOLOGICAL REVIEWS</b>		1B. PUBLICATION NO. 0 0 3 1 6 9 9 7		2. Date of Filing 10-1-92
3. Frequency of Issue Quarterly		3A. No. of Issues Published Annually 4		3B. Annual Subscription Price \$55.00
4. Complete Mailing Address of Known Office of Publication (Street, City, County, State and ZIP+4 Code (for printer)) 428 E. Preston Street, Baltimore, Maryland 21202-3993				
5. Complete Mailing Address of the Headquarters or General Business Office of the Publisher (Not printer) 428 E. Preston Street, Baltimore, Maryland 21202-3993				
6. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Only One NEED BE SHOWN) Publisher (Name and Complete Mailing Address) Williams & Wilkins, 428 E. Preston Street, Baltimore, Maryland 21202-3993				
Editor (Name and Complete Mailing Address) ROBERT E. SCHMIDT, Ph.D., Dept. of Pharmacology & Toxicology, West Virginia University Medical Center, Morgantown, WV 26506				
Managing Editor (Name and Complete Mailing Address)				
7. Owner (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a corporation, its name and address must be stated.) (Show must be completed.)				
American Society for Pharmacology and Experimental Therapeutics		Complete Mailing Address c/o Ray Crockett Executive Director 4550 Rockville Pike Bethesda, MD 20814		
8. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages or Other Securities (If there are none, so state)				
NONE		Complete Mailing Address		
9. For Completion by Nonprofit Organizations Authorized to Mail at Special Rates (9007 Statute 402.12 only) The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Check one)				
<input checked="" type="checkbox"/> Has Not Changed During Preceding 12 Months		<input type="checkbox"/> Has Changed During Preceding 12 Months (If changed, publisher must submit explanation of change with this statement.)		
10A. Extent and Nature of Circulation (Give approximate or exact data)	Average No. Copies Each Issue During Preceding 12 Months	Actual No. Copies of Single Issue Published Nearest to Filing Date		
A. Total No. Copies (Net Press Run)	3675	4505		
B. Paid and Unpaid Circulation 1. Sales Through Dealers and Carriers, Street Vendors and Counter Sales	542	1266		
2. Mail Subscriptions (Paid and Unpaid)	2296	2283		
C. Total Paid and Unpaid Circulation (Sum of B1 and B2)	2838	3549		
D. Free Distribution by Mail, Carrier or Other Means (Samples, Complimentary, and Other Free Copies)	41	31		
E. Total Distribution (Sum of C and D)	2879	3580		
F. Copies Not Distributed 1. Office use, left over, unaccounted, spoiled after printing	796	925		
2. Return from News Agents	NONE	NONE		
G. TOTAL (Sum of E, F1 and 2—should equal net press run shown in A)	3675	4505		
11. I certify that the statements made by me above are correct and complete		Signature and Title of Editor, Publisher, Business Manager, or Owner <i>Alison Wells</i> Publisher		